Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Nur-Vaizura Mohamad
 -- 2510 2023-10-13 02:48:59 |
2 layout
Camila Xu
 Meta information modification 2510 2023-10-13 03:14:31 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Mohamad, N. Pharmacokinetics of Tocotrienol. Encyclopedia. Available online: https://encyclopedia.pub/entry/50231 (accessed on 01 July 2024).
Mohamad N. Pharmacokinetics of Tocotrienol. Encyclopedia. Available at: https://encyclopedia.pub/entry/50231. Accessed July 01, 2024.
Mohamad, Nur-Vaizura. "Pharmacokinetics of Tocotrienol" Encyclopedia, https://encyclopedia.pub/entry/50231 (accessed July 01, 2024).
Mohamad, N. (2023, October 13). Pharmacokinetics of Tocotrienol. In Encyclopedia. https://encyclopedia.pub/entry/50231
Mohamad, Nur-Vaizura. "Pharmacokinetics of Tocotrienol." Encyclopedia. Web. 13 October, 2023.
Pharmacokinetics of Tocotrienol
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ph16101403

Tocotrienols are valuable nutraceuticals due to their numerous pharmacological properties, particularly in preventing or treating non-communicable diseases, including cardiovascular, musculoskeletal, metabolic, and skin disorders, as well as cancers.

bioavailability poor water solubility tocotrienol

1. Introduction

Vitamin E is a fat-soluble antioxidant that can only be produced by plants through photosynthesis, hence it needs to be obtained from foods or supplements, as it plays a crucial role in human nutrition. The distribution of vitamin E in palm oil was reported to be approximately 30% tocopherols and 70% tocotrienols [1]. Tocotrienols have similar structures to tocopherols, with a chromanol head denoted by α, β, γ, or δ, which depends on the position number and methyl groups on the chromanol ring [2]. Tocotrienols differ structurally from tocopherols by the degree of saturation at the side chains, with three double bonds at carbons 3, 7, and 11, whereas tocopherols have saturated phytyl side chains. It was discovered to naturally occur at higher levels in certain cereals and vegetable oils, including palm oil, rice bran oil, barley germ, wheat germ, and annatto [3][4][5][6][7].
Tocotrienols are valuable nutraceuticals due to their numerous pharmacological properties, particularly in preventing or treating non-communicable diseases, including cardiovascular, musculoskeletal, metabolic, and skin disorders, as well as cancers [8]. Tocotrienols have biochemical functions that are directly or indirectly impacted by their antioxidant properties, which prevent the non-enzymatic oxidation of various cell components by molecular oxygen and free radicals. In several studies, tocotrienols have been shown to inhibit free radical production via the induction of enzymes such as superoxide dismutase [9][10] and glutathione peroxidase, which neutralise superoxide radical-produced free radicals [11]. In addition, tocotrienols have been extensively studied for their anti-inflammatory properties, and promising scientific evidence has been presented. In light of the fact that inflammation is a full array of physiological responses to a foreign organism, it has been established that inflammation is a significant element in the progression of numerous chronic diseases and disorders. Tocotrienols have been demonstrated to inhibit the expression of inflammatory mediators such as tumour necrosis factor-alpha [10], interleukin [IL]-1 [12], IL-6 [13], and nitric oxide synthase [14]. Antioxidants protect tissues from damage against reactive oxygen species and other free radicals, indirectly preventing unwanted inflammatory responses from occurring in the first place.
Despite their medicinal value, translating tocotrienols into a viable medicinal product remains challenging due to their low oral bioavailability. Oral administration remains the preferred choice for drug delivery due to its safety, patient compliance, and self-administration capacity. Although oral delivery is the most convenient, it is also limited by a number of barriers in the gastrointestinal tract (GIT) [15]. Upon oral administration, drug solubilisation in the GIT is essential for absorption, as insufficient dissolution can cause incomplete absorption, low bioavailability, and high variability [16]. Tocotrienol has unfavourable physicochemical properties as a highly viscous oil that is nearly insoluble in water and readily oxidised by atmospheric oxygen. Other limitations exist, such as saturable intestinal absorption and the selectivity of the transfer protein [17][18]. These physicochemical, biological, physiological, and anatomical factors act independently and in concern to limit tocotrienol bioavailability and prevent effective oral delivery [19]. Using a rat model, an in vivo study found that intraperitoneal and intramuscular administration of tocotrienols resulted in minimal absorption, whereas oral administration resulted in incomplete absorption of tocotrienols [20]. Researchers have invented various methods to improve the bioavailability of these compounds. One of the innovations is a self-emulsifying drug delivery system (SEDDS), an isotropic mixture of oils, surfactants, co-surfactants, and co-solvents. SEDDSs can improve the oral absorption of highly lipophilic drug compounds by maintaining them in a solubilised state, thereby preventing an improperly water-soluble compound from solubilising and subsequently dissolving [21]. The oral bioavailability of each tocotrienol form was reported low in previous studies, with α-tocotrienol at 27.7%, γ-tocotrienol at 9.1%, and δ-tocotrienol at 8.5% [22]. Therefore, without α-tocopherol, tocotrienol absorption is virtually nonexistent without suitable conditions and optimal fat levels. The findings also showed that the elimination half-lives of several tocotrienol forms ranged between 2.3 and 4.4 h, much shorter than α-tocopherol elimination half-lives, which lasted 48 to 72 h [23][24][25]. The poor and inconsistent oral bioavailability of fat-soluble compounds in the GI led researchers to explore solutions to overcome these issues and ensure positive therapeutic effects in humans.

2. Pharmacokinetics of Tocotrienol

Tocotrienol exhibits many beneficial effects, but its poor oral bioavailability aids in its application as a future therapeutic agent. Many factors influence tocotrienol pharmacokinetics, such as their solubility, absorption, distribution, and elimination. Absorption is the process by which drugs or substances enter the body. Given any method other than intravenously, drugs or substances molecules must pass tissue barriers such as the skin epithelium, subcutaneous tissue, gut endothelium, and capillary wall to enter the blood. Meanwhile, distribution refers to how drugs or other substances are transported throughout the body. It is then followed by the metabolism or biotransformation of toxicants that function to detoxify, which is divided into two stages: Phase I and Phase II. Phase I includes oxidation, hydrolysis, and reduction mechanisms, where these reactions, catalysed by hepatic enzymes, generally convert foreign compounds into phase II derivatives. Phase I products can be excreted as such if polar solubility permits translocation.
Meanwhile, Phase II involves the conjugation or synthesis reactions. Standard conjugates include glucuronides, acetylation, and glycine combinations [26]. Lastly, the excretion removes metabolic waste from the body, mainly through various processes performed by various body parts and internal organs. The effectiveness of vitamin E in those tissues is significantly influenced by the delivery of orally administered vitamin E to vital organs. Thus, mechanisms underlying the delivery of absorbed vitamin E to tissues have been the subject of active investigation. As the palm vitamin E mixture contains both α-tocopherol and tocotrienols, interactions between these compounds would affect their pharmacokinetics. Of note, α-tocopherol is suggested to affect the bioavailability of tocotrienol significantly. In a study by Qureshi et al., 33 healthy male subjects were supplemented with δ-tocotrienol at 125, 250, or 500 mg/d, dose dependently increasing the plasma area under the curve (AUC). The findings indicated that tocotrienols augmented in the absence of tocopherols, as δ-tocotrienol had better bioavailability, thus enhancing therapeutic properties by reducing the levels of cytokines related to inflammation [23].

2.1. Absorption of Tocotrienol

The bioavailability of an orally administered compound comprises three parts products, including the dissolved and the part that escapes degradation in the lumen. Next is the fraction that absorbs and penetrates the entire intestinal membrane and escapes the intestinal first-pass metabolism. The last part is the fraction that escapes the liver’s first-pass metabolism [27]. Tocotrienols are natural lipophilic compounds that exist as oily liquids. Their oral bioavailability was poor and erratic due to low aqueous solubility and miscibility [20]. It is widely believed that all forms of vitamin E are absorbed by passive diffusion [28][29]. This type of diffusion is defined as a substance moving toward the concentration gradient without any energy input from a higher concentration area to a lower concentration area. Thus, the therapeutic level of tocotrienol might be difficult to reach in the blood and target tissue using oral administration [30]. Previous studies have discovered that taking tocotrienols with food increases the amount of tocotrienols absorbed through the intestinal wall. Food like a fatty meal enhances tocotrienol solubility due to the formation of mixed micelles that increase the area of absorption in the intestines caused by stimulating bile salts and pancreatic enzyme secretion [25][31]. Indeed, mixed micelles can solubilise hydrophobic components and diffuse into the unstirred water layer (glycocalix) to approach the brush border membrane of the enterocytes. In addition, food also increases the lymph lipid precursor pool inside the enterocytes, eventually enhancing lymphatic transport. Vitamin E does not stabilise for long in the digestive tract after being ingested, leading to a rapid attack by the digestive enzyme pancreatic lipase before breaking down fat molecules into tiny pieces called fatty acids and mono-glycerides.
According to Fairus et al., tocotrienols disappear rapidly from plasma within 24 h, raising questions about their biological activities [32]. This might be partly due to the low affinity of the α-tocopherol transport protein (α-TTP) for tocotrienols. The findings showed that the repackaging of α-tocopherol in the liver into very low-density lipoprotein cholesterol results in a longer shelf life and higher plasma concentrations of α-tocopherol. A different pathway for tocotrienol absorption has been proposed, which is independent to TTP [33]. In addition, some researchers identified that absorption of γ-tocotrienol was not complete, although an increase in solubility after being administrated with food significantly enhanced bioavailability [20]. Increased levels of γ-tocotrienol in the intestinal lumen cause saturation of tocotrienol absorption, which explains why increasing the dose does not increase tocotrienol bioavailability, indicating barriers and specific mechanisms of oral absorption transport by primary enterocytes. The intestinal uptake of γ-tocotrienol is inversely proportional to its presence in the intestinal lumen, which strongly suggests that the transportation across the intestinal membrane involves a carrier-mediated process [34]. Studies showed that the intestinal permeability of γ-tocotrienol decreased at a concentration of more than 25 µM, indicating that the intestinal uptake of the same was saturable, and a carrier-mediated process was involved. The in situ findings revealed the role of Niemann-Pick C1-like 1 (NPC1L1) as an intestinal transporter in both γ-tocotrienol and α-tocopherol intestinal uptake [34][35]. NPC1L1 is a critical mediator of cholesterol absorption and is mainly found in the GIT epithelial cells and hepatocytes.

2.2. Distribution of Tocotrienol

After oral administration, tocotrienol is absorbed from the intestine and transported to the systemic circulation through the lymphatic pathway. It is then incorporated into triglyceride-rich chylomicrons, and some of it is transported to other organs. The distribution of tocotrienol was examined by considering the tolerable upper intake level of vitamin E. The experiment using rats set the limit for tocotrienol daily intake to not exceed an amount in rats equivalent to the acceptable daily intake for humans, approximately 600–800 mg/day [36]. A study by Ikeda et al. reported that two isomers of tocotrienol (α and γ) were distributed in the adipose tissues and skin of the rats fed with palm tocotrienol diet [37]. However, these palm tocotrienols were not detected in the brain, liver, kidney, or plasma. A different source of tocotrienol from rice bran also showed that γ-tocotrienol was predominantly present in the adipose tissue and highly in the skin and heart [38]. Other findings demonstrated that γ-tocotrienol was predominant in adipose tissue on day 3 and was still higher on day 14 after administering a single dose of emulsified γ-tocotrienol subcutaneous injection. This finding aligned with previous studies in which γ -tocotrienol was administered in the diet and showed a preference for accumulation in adipose tissue regardless of the route of administration. Interestingly, γ-tocotrienol levels in the heart and spleen increased significantly on day 14 compared to day 3 [39]. Of note, tocotrienols predominantly accumulated in various sites of white adipose tissues, including epididymal fat, perirenal fat, and visceral fat, as well as in the skin after supplementation with a few concentrations of tocotrienol [40]. Increasing the tocotrienols intake increased its concentration in most tissues, although no dose-dependent effects were observed in the brain site. Despite unclear mechanisms on how tocotrienols selectively accumulate in these tissues, the researchers hypothesise that it depends on the affinity of tocotrienol towards the vitamin E-binding proteins and also due to cytochrome P450 expression level in each organ.
A long-term dietary intake of tocotrienol leads to the accumulation in adipose tissue for 8 weeks [41]. Interestingly, the dietary α-tocopherol reduced the α-tocotrienol but not γ-tocotrienol concentration in various tissues. The findings demonstrated a significant amount of α- and γ-tocotrienol accumulated in the perirenal adipose tissues and epididymal fat of rats fed with a tocotrienol mixture. In contrast, other findings showed that γ-tocopherol concentrations were lower in the adipose tissues than in some tissues, including the adrenal gland, liver, and spleen of rats fed with γ-tocopherol [42]. Although the affinity of α-tocotrienol for α-TTP is nearly identical to γ-tocopherol, it does not explain the tissue-specific accumulation of tocotrienol for α-TTP. Furthermore, it was observed that the concentrations of α- and γ-tocotrienol in perirenal adipose tissue were 9.4- and 36.4-fold greater, respectively, than those in the serum. In contrast, the concentrations of α- and γ-tocopherol were only 0.9- and 1.7-fold higher in adipose tissue compared to serum. The findings suggest that adipose tissue preferentially absorbed or stored tocotrienol than tocopherol.

2.3. Metabolism of Tocotrienol

Vitamin E has several forms, containing the same chromanol ring and a hydrophobic side chain 13 carbons long. Tocotrienols differ from tocopherols in that they have an unsaturated side chain that contains three double bonds at the 3′, 7′, and 11 positions, as opposed to tocopherols. Upon supplementation, tocotrienols accumulate only in the skin and adipose tissues, whereas tocopherols can be found in most tissues [43][44]. These findings show that tocotrienols are metabolised and eliminated more extensively and quickly than tocopherols. Once tocotrienols and tocopherols are absorbed and delivered to the liver, their fates will likely undergo metabolism and excretion.
Findings demonstrated that the tocotrienols are metabolised essentially, like tocopherols, as few metabolites degraded from γ-tocotrienol, like carboxyethyl hydroxychroman, carboxymethylbutyl hydroxychroman, carboxymethylhexenyl hydroxychroman, and carboxydimethyloctenyl hydroxychroman, were identified, similar to α-tocopherol [45]. Tocopherols and tocotrienols are metabolised without modifying the chromanol ring through oxidative degradation of the hydrophobic side chain. The mechanism involved was cytochrome P450 catalysed, hydroxylation, and oxidation of the 13′-carbon to form 13′-carboxy chromanol (13′-COOH), followed by a series of stepwise β-oxidations to remove a 2- or 3-carbon moiety from the side chain each cycle [46][47]. Recently, researchers discovered that γ-tocotrienol undergoes metabolism to produce novel metabolites, including sulphated 9′, 11′, and 13′-carboxy chromanol, both in human lung epithelial A549 cells and in rats [48]. In this study, sulfation likely occurs parallel to β-oxidation during tocopherol metabolism, indicating tocotrienol is metabolized much faster and more extensively. Similarly, the plasma concentrations of most metabolites were higher in rats supplemented with γ-tocotrienol than in rats fed with tocopherol [49].

2.4. Excretion of Tocotrienol

There are two main routes through which vitamin E is excreted. The most common route of excretion is through bile, which is then excreted in faeces after passing through the liver. Alternatively, vitamin E can be excreted in the urine after chain shortening, similar to β-oxidation, making it more water soluble. Due to a lack of TTP, α-tocopherol is not secreted back into the bloodstream. Therefore, an excess of vitamin E is not accumulated in the liver because it does not accumulate toxic amounts of vitamin E, which leads it to be metabolised and excreted in the bile [50]. A recent investigation revealed that α-tocopherol is found in urine as the metabolite α-carboxyethyl-hydroxychroman (CEHC), where the urinary α-CEHC excretion increased by 0.086 μmol/g creatinine with every 1 mg (2.3-μmol) increase in dietary α-tocopherol [51]. CEHC in urine increased in response to tocotrienol supplements, suggesting that tocotrienols are metabolised in the same way as tocopherols [52]. A study by Lodge et al. found that the γ-CEHC excretion time course increased urinary γ-CEHC at 6 h and a peak at 9 h following ingestion of 125 mg γ-tocotrienyl acetate [52]. However, the percentage of the dose recovered as metabolites in the urine is low (only up to 8%). In addition the long-chain carboxychromanols, especially 13′-COOHs, were found in tissues and faeces in animals supplemented with γ-tocopherol, δ-tocopherol, and γ-tocotrienol [53]. Both tocotrienol and tocopherol are bioavailable in the plasma according to research on vitamin E forms in rats, and they are primarily excreted as unmetabolized forms and long-chain metabolites, including 13′-COOHs in faeces, with more metabolites from tocotrienols than from tocopherols [53].

References

  1. Sundram, K.; Sambanthamurthi, R.; Tan, Y.-A. Palm fruit chemistry and nutrition. Asia Pac. J. Clin. Nutr. 2003, 12, 355–362.
  2. Sen, C.K.; Khanna, S.; Roy, S. Tocotrienols in health and disease: The other half of the natural vitamin E family. Mol. Asp. Med. 2007, 28, 692–728.
  3. Ng, M.H.; Choo, Y.M.; Ma, A.N.; Chuah, C.H.; Hashim, M.A. Separation of vitamin E (tocopherol, tocotrienol, and tocomonoenol) in palm oil. Lipids 2004, 39, 1031–1035.
  4. Shammugasamy, B.; Ramakrishnan, Y.; Manan, F.; Muhammad, K. Rapid Reversed-Phase Chromatographic Method for Determination of Eight Vitamin E Isomers and γ-Oryzanols in Rice Bran and Rice Bran Oil. Food Anal. Methods 2015, 8, 649–655.
  5. Moreau, R.A.; Wayns, K.E.; Flores, R.A.; Hicks, K.B. Tocopherols and Tocotrienols in Barley Oil Prepared from Germ and Other Fractions from Scarification and Sieving of Hulless Barley. Cereal Chem. 2007, 84, 587–592.
  6. Kumar, G.S.; Krishna, A.G. Studies on the nutraceuticals composition of wheat derived oils wheat bran oil and wheat germ oil. J. Food Sci. Technol. 2015, 52, 1145–1151.
  7. Tan, B.; Brzuskiewicz, L. Separation of tocopherol and tocotrienol isomers using normal- and reverse-phase liquid chromatography. Anal. Biochem. 1989, 180, 368–373.
  8. Wong, S.K.; Kamisah, Y.; Mohamed, N.; Muhammad, N.; Masbah, N.; Fahami, N.A.M.; Mohamed, I.N.; Shuid, A.N.; Saad, Q.M.; Abdullah, A. Potential Role of Tocotrienols on Non-Communicable Diseases: A Review of Current Evidence. Nutrients 2020, 12, 259.
  9. Nazrun, A.; Khairunnur, A.; Norliza, M.; Norazlina, M. Effects of palm tocotrienols on oxidative stress and bone strength in ovariectomised rats. Med. Health 2008, 3, 247–255.
  10. Radhakrishnan, A.; Tudawe, D.; Chakravarthi, S.; Chiew, G.S.; Haleagrahara, N. Effect of γ-tocotrienol in counteracting oxidative stress and joint damage in collagen-induced arthritis in rats. Exp. Ther. Med. 2014, 7, 1408–1414.
  11. Devi, R.R.; Arumughan, C. Antiradical efficacy of phytochemical extracts from defatted rice bran. Food Chem. Toxicol. 2007, 45, 2014–2021.
  12. Norazlina, M.; Lee, P.L.; Lukman, H.I.; Nazrun, A.S.; Ima-Nirwana, S. Effects of vitamin E supplementation on bone metabolism in nicotine-treated rats. Singap. Med. J. 2007, 48, 195–199.
  13. Ahmad, N.S.; Khalid, B.A.; Luke, D.A.; Nirwana, S. Tocotrienol offers better protection than tocopherol from free radical-induced damage of rat bone. Clin. Exp. Pharmacol. Physiol. 2005, 32, 761–770.
  14. Qureshi, A.A.; Reis, J.C.; Qureshi, N.; Papasian, C.J.; Morrison, D.C.; Schaefer, D.M. δ-Tocotrienol and quercetin reduce serum levels of nitric oxide and lipid parameters in female chickens. Lipids Health Dis. 2011, 10, 39.
  15. Shah, M.K.; Khatri, P.; Vora, N.; Patel, N.K.; Jain, S.; Lin, S. Lipid nanocarriers: Preparation, characterization and absorption mechanism and applications to improve oral bioavailability of poorly water-soluble drugs. Biomed. Appl. Nanoparticles 2019, 117–147.
  16. Gao, P.; Morozowich, W. Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs. Expert Opin. Drug Deliv. 2006, 3, 97–110.
  17. Abuasal, B.S.; Qosa, H.; Sylvester, P.W.; Kaddoumi, A. Comparison of the intestinal absorption and bioavailability of γ-tocotrienol and α-tocopherol: In vitro, in situ and in vivo studies. Biopharm. Drug Dispos. 2012, 33, 246–256.
  18. Lim, Y.; Traber, M.G. Alpha-Tocopherol Transfer Protein (α-TTP): Insights from Alpha-Tocopherol Transfer Protein Knockout Mice. Nutr. Res. Pr. 2007, 1, 247–253.
  19. Boyd, B.J.; Bergström, C.A.; Vinarov, Z.; Kuentz, M.; Brouwers, J.; Augustijns, P.; Brandl, M.; Bernkop-Schnürch, A.; Shrestha, N.; Préat, V. Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. Eur. J. Phar. Sci. 2019, 137, 104967.
  20. Yap, S.P.; Yuen, K.H.; Lim, A.B. Influence of route of administration on the absorption and disposition of alpha-, gamma- and delta-tocotrienols in rats. J. Pharm. Pharmacol. 2003, 55, 53–58.
  21. Gursoy, R.N.; Benita, S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacothe.r 2004, 58, 173–182.
  22. Yuen, K.-H.; Ng, B.-H.; Wong, J.-W. 22 Absorption and Disposition of Tocotrienols, Tocotrienols: Vitamin E Beyond Tocopherols; CRC Press: Taylor & Francis Group, Boca Raton, FL, USA, 2008; p. 297.
  23. Qureshi, A.; Khan, D.; Saleem, S.; Silswal, N.; Trias, A.; Tan, B. Pharmacokinetics and bioavailability of annatto δ-tocotrienol in healthy fed subjects. J. Clin. Exp. Cardiol. 2015, 6, 1–13.
  24. Qureshi, A.A.; Khan, D.A.A.; Silswal, N.; Saleem, S.; Qureshi, N. Evaluation of Pharmacokinetics, and Bioavailability of Higher Doses of Tocotrienols in Healthy Fed Humans. J. Clin. Exp. Cardiol. 2016, 7, 434.
  25. Yap, S.P.; Yuen, K.H.; Wong, J.W. Pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under different food status. J. Pharm. Pharmacol. 2001, 53, 67–71.
  26. Iyanagi, T. Molecular Mechanism of Phase I and Phase II Drug-Metabolizing Enzymes: Implications for Detoxification. Int. Rev. Cytol. 2007, 260, 35–112.
  27. Cao, X.; Gibbs, S.T.; Fang, L.; Miller, H.A.; Landowski, C.P.; Shin, H.-C.; Lennernas, H.; Zhong, Y.; Amidon, G.L.; Yu, L.X.; et al. Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model. Pharm. Res. 2006, 23, 1675–1686.
  28. Alqahtani, S.; Alayoubi, A.; Nazzal, S.; Sylvester, P.W.; Kaddoumi, A. Nonlinear Absorption Kinetics of Self-Emulsifying Drug Delivery Systems (SEDDS) Containing Tocotrienols as Lipophilic Molecules: In Vivo and In Vitro Studies. AAPS J. 2013, 15, 684–695.
  29. Abuasal, B.S.; Lucas, C.; Peyton, B.; Alayoubi, A.; Nazzal, S.; Sylvester, P.W.; Kaddoumi, A. Enhancement of Intestinal Permeability Utilizing Solid Lipid Nanoparticles Increases γ-Tocotrienol Oral Bioavailability. Lipids 2012, 47, 461–469.
  30. Sylvester, P.W.; Shah, S.J. Mechanisms mediating the antiproliferative and apoptotic effects of vitamin E in mammary cancer cells. Front. Biosci. 2005, 10, 699–709.
  31. Fu, J.-Y.; Che, H.-L.; Tan, D.M.-Y.; Teng, K.-T. Bioavailability of tocotrienols: Evidence in human studies. Nutr. Metab. 2014, 11, 5.
  32. Fairus, S.; Nor, R.M.; Cheng, H.M.; Sundram, K. Alpha-tocotrienol is the most abundant tocotrienol isomer circulated in plasma and lipoproteins after postprandial tocotrienol-rich vitamin E supplementation. Nutr. J. 2012, 11, 5.
  33. Gee, P.T. Vitamin E - essential knowledge for supplementation. Lipid Technol. 2011, 23, 79–82.
  34. Abuasal, B.; Sylvester, P.W.; Kaddoumi, A. Intestinal Absorption of γ-Tocotrienol Is Mediated by Niemann-Pick C1-Like 1: In Situ Rat Intestinal Perfusion Studies. Drug Metab. Dispos. 2010, 38, 939–945.
  35. Narushima, K.; Takada, T.; Yamanashi, Y.; Suzuki, H. Niemann-Pick C1-Like 1 Mediates α-Tocopherol Transport. Mol. Pharmacol. 2008, 74, 42–49.
  36. Hathcock, J.N.; Azzi, A.; Blumberg, J.; Bray, T.; Dickinson, A.; Frei, B.; Jialal, I.; Johnston, C.S.; Kelly, F.J.; Kraemer, K. Vitamins E and C are safe across a broad range of intakes. Am. J. Clin. Nutr. 2005, 81, 736–745.
  37. Ikeda, S.; Toyoshima, K.; Yamashita, K. Dietary Sesame Seeds Elevate α- and γ-Tocotrienol Concentrations in Skin and Adipose Tissue of Rats Fed the Tocotrienol-Rich Fraction Extracted from Palm Oil. J. Nutr. 2001, 131, 2892–2897.
  38. Kawakami, Y.; Tsuzuki, T.; Nakagawa, K.; Miyazawa, T. Distribution of Tocotrienols in Rats Fed a Rice Bran Tocotrienol Concentrate. Biosci. Biotechnol. Biochem. 2007, 71, 464–471.
  39. Deng, L.; Peng, Y.; Wu, Y.; Yang, M.; Ding, Y.; Chen, Q.; Fu, Q. Tissue distribution of emulsified γ-tocotrienol and its long-term biological effects after subcutaneous administration. Lipids Health Dis. 2014, 13, 66.
  40. Shibata, A.; Nakagawa, K.; Shirakawa, H.; Kobayashi, T.; Kawakami, Y.; Takashima, R.; Ohashi, A.; Sato, S.; Ohsaki, Y.; Kimura, F. Physiological Effects and Tissue Distribution from Large Doses of Tocotrienol in Rats. Biosci. Biotechnol. Biochem. 2012, 76, 1805–1808.
  41. Ikeda, S.; Tohyama, T.; Yoshimura, H.; Hamamura, K.; Abe, K.; Yamashita, K. Dietary α-tocopherol decreases α-tocotrienol but not γ-tocotrienol concentration in rats. J. Nutr. 2003, 133, 428–434.
  42. Uchida, T.; Abe, C.; Nomura, S.; Ichikawa, T.; Ikeda, S. Tissue distribution of α- and γ-tocotrienol and γ-tocopherol in rats and interference with their accumulation by α-tocopherol. Lipids 2012, 47, 129–139.
  43. Okabe, M.; Oji, M.; Ikeda, I.; Tachibana, H.; Yamada, K. Tocotrienol Levels in Various Tissues of Sprague-Dawley Rats after Intragastric Administration of Tocotrienols. Biosci. Biotechnol. Biochem. 2002, 66, 1768–1771.
  44. Yamashita, K.; Ikeda, S.; Iizuka, Y.; Ikeda, I. Effect of sesaminol on plasma and tissue α-tocopherol and α-tocotrienol concentrations in rats fed a vitamin E concentrate rich in tocotrienols. Lipids 2002, 37, 351–358.
  45. Birringer, M.; Pfluger, P.; Kluth, D.; Landes, N.; Brigelius-Flohé, R. Identities and Differences in the Metabolism of Tocotrienols and Tocopherols in HepG2 Cells. J. Nutr. 2002, 132, 3113–3118.
  46. Parker, R.S.; Sontag, T.J.; Swanson, J.E.; McCormick, C.C. Discovery, characterization, and significance of the cytochrome P450 omega-hydroxylase pathway of vitamin E catabolism. Ann. N. Y. Acad. Sci. 2004, 1031, 13–21.
  47. Sontag, T.J.; Parker, R.S. Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism. Novel mechanism of regulation of vitamin E status. J. Biol. Chem. 2002, 277, 25290–25296.
  48. Qing, J.; Helene, F.; Wood, K.V.; Xinmin, Y. Identification and quantitation of novel vitamin E metabolites, sulfated long-chain carboxychromanols, in human A549 cells and in rats. J. Lipid Res. 2007, 48, 1221–1230.
  49. Freiser, H.; Jiang, Q. γ-Tocotrienol and γ-tocopherol are primarily metabolized to conjugated 2-(β-carboxyethyl)-6-hydroxy-2, 7, 8-trimethylchroman and sulfated long-chain carboxychromanols in rats. J. Nutr. 2009, 139, 884–889.
  50. Traber, M.G. Mechanisms for the prevention of vitamin E excess. J. Lipid Res. 2013, 54, 2295–2306.
  51. Lebold, K.M.; Ang, A.; Traber, M.G.; Arab, L. Urinary α-carboxyethyl hydroxychroman can be used as a predictor of α-tocopherol adequacy, as demonstrated in the Energetics Study. Am. J. Clin. Nutr. 2012, 96, 801–809.
  52. Lodge, J.K.; Ridlington, J.; Leonard, S.; Vaule, H.; Traber, M.G. Alpha- and gamma-tocotrienols are metabolized to carboxyethyl-hydroxychroman derivatives and excreted in human urine. Lipids 2001, 36, 43–48.
  53. Liu, K.Y.; Jiang, Q. Tocopherols and Tocotrienols Are Bioavailable in Rats and Primarily Excreted in Feces as the Intact Forms and 13′-Carboxychromanol Metabolites. J. Nutr. 2020, 150, 222–230.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Pharmacology & Pharmacy
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Nur-Vaizura Mohamad
View Times: 178
Revisions: 2 times (View History)
Update Date: 13 Oct 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback